论文部分内容阅读
目的探讨p53和C-erbB-2在乳腺癌组织中的表达及其与乳腺癌临床分期的相关性。方法采用免疫组化法检测86例乳腺癌组织中p53和C-erbB-2的表达情况,结合临床分期进行相关性分析。结果乳腺癌组织中p53和C-erbB-2表达率分别为37.2%和52.3%。p53和C-erbB-2表达与临床分期相关。结论 p53和C-erbB-2检测对判断乳腺癌预后有重要意义,联合检测p53和C-erbB-2可以提高评价乳腺癌预后的敏感度。
Objective To investigate the expression of p53 and C-erbB-2 in breast cancer tissues and its correlation with clinical stage of breast cancer. Methods Immunohistochemistry was used to detect the expression of p53 and C-erbB-2 in 86 cases of breast cancer. The correlation analysis was performed with the clinical stage. Results The expression rates of p53 and C-erbB-2 in breast cancer tissues were 37.2% and 52.3%, respectively. The expression of p53 and C-erbB-2 correlated with clinical stage. Conclusion The detection of p53 and C-erbB-2 has important significance in judging the prognosis of breast cancer. Combined detection of p53 and C-erbB-2 can increase the sensitivity of evaluating breast cancer prognosis.